by Victoria Radke | Nov 5, 2020
Thierry Abribat, PhD, chief executive officer of Amolyt Pharma describes AZP-3601, a drug in development to treat hypoparathyroidism. Persons with hypoparathyroidism show abnormally low levels of calcium in the blood and high levels of phosphorus...
by Victoria Radke | Oct 20, 2020
Susan Samson, MD, PhD, of Baylor College of Medicine explains why it often takes 5 to 10 years for a person with acromegaly to be properly diagnosed. This is extremely problematic given that treatments are available for this condition. Acromegaly is a rare...
by Victoria Radke | Oct 19, 2020
The US Food and Drug Administration (FDA) has approved Venclexta (venetoclax) to treat elderly patients with acute myeloid leukemia (AML). More specifically, the drug is approved in combination with azacitidine, or decitabine, or low-dose cytarabine (LDAC) for the...
by Victoria Radke | Sep 28, 2020
The U.S. Food and Drug Administration (FDA) has approved mepolizumab (Nucala) for the treatment of hypereosinophilic syndrome (HES) in adults and children 12 years and older. This indication is the first approval for treating HES in almost 14 years. HES is a group of...
